Alkermes to Participate in Upcoming Investor Conferences
Werte in diesem Artikel
DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences.
TD Cowen 45th Annual Health Care Conference
Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT)
Leerink Partners Global Healthcare Conference 2025
Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET (3:20 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alkermes-to-participate-in-upcoming-investor-conferences-302386278.html
Ausgewählte Hebelprodukte auf Alkermes
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Alkermes
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Alkermes PLC
Analysen zu Alkermes PLC
Datum | Rating | Analyst | |
---|---|---|---|
31.05.2019 | Alkermes Neutral | H.C. Wainwright & Co. | |
14.12.2018 | Alkermes Underperform | Wolfe Research | |
07.08.2018 | Alkermes Hold | Stifel, Nicolaus & Co., Inc. | |
06.06.2018 | Alkermes Buy | B. Riley FBR, Inc. | |
16.10.2017 | Alkermes Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
07.08.2018 | Alkermes Hold | Stifel, Nicolaus & Co., Inc. | |
06.06.2018 | Alkermes Buy | B. Riley FBR, Inc. | |
07.10.2015 | Alkermes Overweight | Barclays Capital | |
21.05.2015 | Alkermes Overweight | Barclays Capital | |
08.01.2015 | Alkermes Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
31.05.2019 | Alkermes Neutral | H.C. Wainwright & Co. | |
16.10.2017 | Alkermes Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Alkermes Underperform | Wolfe Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Alkermes PLC nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen